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Picture this. You have a research question of international
importance. Against the odds, you have secured non-
commercial funding for a well-designed multicentre project
that will answer the question. Naturally, you must obtain
research ethics committee (REC) approval. You apply to an
REC online. After clarifying questions about your
application on just one occasion, you get a decision at no
charge, within 60 days, and it is valid for the whole of your
country.
While this scenario is a fantasy in countries such as the
USA,1 Canada,2 and Australia,3 a recent Department of
Health (DoH) report celebrates this new era of REC
operation in the UK.4 But to what extent do the procedures
in the UK meet this ideal, and have they improved? Do
other regulatory hurdles lurk in the shadow cast by the
mighty new REC system? In other words, is British
researchers’ long battle against red tape over?
FIRST, LOCAL RESEARCH
ETHICS COMMITTEES . . .
Although the DoH recommended the creation of informal
RECs as long ago as 1968, it was not until 1991 that it
formally delegated responsibility for ethical review of
research in the UK National Health Service (NHS) to local
research ethics committees (LRECs) based in each health
authority.5 Although LRECs’ standards of practice were
said to be good,6 the evidence that their process and
consistency were poor was overwhelming.7–18 The
application procedures were heterogeneous, uncoordinated,
bureaucratic, expensive and time-consuming, which
probably resulted in unethical delays to valuable research.19
Worst of all, their voluntary membership developed varying
levels of autonomy and a diversity of working practices that
fostered inconsistent and unpredictable decisions, due—in
part—to their rapidly expanding workloads and a paucity of
guidelines.20
This decentralized system posed particular problems for
the growing number of multicentre research projects,
which required approval from many different RECs. Simple
solutions were proposed: administrative and technological
cures for the bureaucratic disease, and the formation of
regional RECs to facilitate multicentre research.21
. . . THEN, MULTICENTRE RESEARCH
ETHICS COMMITTEES
So it was that in 1997 a standardized system for the review
of multicentre research began with the creation of 13
multicentre research ethics committees (MRECs).22 A
multicentre research project (taking place over five or more
LREC geographical boundaries) required the opinion of just
one MREC about its ethics. Once approved, its decision and
details of the project had to be distributed to every LREC in
the geographical location of the study, whose executive
subcommittee was only allowed to consider—within a
proscribed timeframe—the suitability of the local site,
researcher(s) and/or facilities.23 Furthermore, in recogni-
tion of the minimal risk to patients in multicentre
observational epidemiology and health services research,
MREC standard operating procedures were modified to
tailor the extent and duration of LREC review to the degree
of patient contact in these research designs.
This system was designed both to minimize the burden
of ethical review for LRECs and to reduce the unsatisfactory
delays that they had caused for researchers in the past.
MRECs probably achieved the first aim, but LRECs seemed
to have difficulty with their altered role and initially—at
least—persisted in their time-consuming, costly, bureau-
cratic and variable ways.24–31 Both the successes and the
shortcomings of the MREC system were acknowl-
edged.32,33 Suggestions for improvement were made25,34
and a national survey of researchers, research sponsors, and
LRECs involved in the first year of the MREC system was
conducted. Once again, a national body was called for to
further improve training, guidance, support, payment, and
communication with REC members.21,35
. . . NOW, THE CENTRAL OFFICE FOR RESEARCH
ETHICS COMMITTEES (COREC)
The DoH established COREC in 2000 to implement,
develop, maintain, standardize and oversee MREC/LREC
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on the process of ethical review. Although COREC works on
behalf of the DoH in England, its mission statement
indicates that it works closely with colleagues in Scotland,
Wales and Northern Ireland. While COREC distributes
rather than centralizes decision-making, it is the organiza-
tional hub of the REC process. COREC liaises with DoH
over the regulations implementing the European Clinical
Trials Directive (2001/20/EC). The directive’s aspirations
for good clinical practice and REC operation (such as the
60-day limit on reviewing applications) have been applied
in the UK to all types of NHS research, not just clinical
trials.
But to what extent has this reorganization of REC
operation facilitated ethical research? There is no doubt that
research will benefit because ethical review of any project,
however large, will occur once and will be communicated
within 60 days of application (see www.corec.org.uk for
exact details).36 COREC has implemented laudable
mechanisms to improve RECs’ speed of review, consis-
tency, standards, training and appeals procedures, but
evidence of their effect has not been provided (yet).
Researchers’ pleas for user-friendly online forms have been
heeded. But some researchers have still found COREC’s
57-page form too long, complicated, and time-consuming
for their liking,37,38 and asked for the additional 11-page
NHS research and development (R&D) data collection form
to be disentangled from the process of ethical review.38
Happily, researchers can apply in parallel for both REC
and R&D approval of their project. But—and this is a
big but—for multicentre projects with REC approval, it
seems absurdly duplicative to require both a local ‘site-
specific assessment’ (submitted by a named local investi-
gator) as well as R&D management approval at every site
involved. Ironically, while researchers continue to dissent,
others argue that the wording of the UK regulations
implementing the ‘industry-led’ European clinical trials
directive has led to ‘a subtle change in emphasis from the
protection of research participants to the facilitation of
research’.39
THE REPORT OF THE AD HOC ADVISORY
GROUP ON THE OPERATION OF NHS
RESEARCH ETHICS COMMITTEES
The recent, commendable DoH report comprises both a
succinct salute to the improved operation of RECs since
COREC, as well as clear recommendations for finessing the
REC and R&D systems.4 Surprisingly, there was no REC
representation on the Advisory Group, although the
committee did visit COREC. One would expect those
most concerned about REC operation to have made the
largest number of submissions during the report’s
consultation period: of the 75 written and oral responses,
the majority were from the research community, 18 (24%)
were affiliated to RECs, and 11 (17%) were affiliated to
R&D departments. Sadly, for a system that should be
consistent across the UK and indeed further afield, one of
the consequences of devolution was that the Advisory
Group’s remit was only to review COREC and English and
Scottish RECs (although there were observers on the Group
from Scotland, Wales and Northern Ireland).
The DoH report made several important recommenda-
tions of interest to researchers.
First, surveys, health service evaluation, and studies of
NHS staff should be deemed exempt from ethical review.
Without specifying which particular study designs should be
exempt, there is a risk that requiring REC review of some
types of observational research but not audit will perpetuate
an existing double standard.40 Ethical concerns about
confidentiality and data protection are equally applicable
to observational research and audit.41
Secondly, the report emphasizes that an REC’s main
task is ethical rather than scientific review. Therefore,
the focus of REC members’ training should be on
ethical issues, their training should provide quality
assurance thereby making RECs’ decisions more consis-
tent;42 these will be monitored by a new system
of peer review between RECs. RECs should, however,
accept prior scientific peer review of a project (for
example, by a grant-giving body) in all but exceptional
cases (no examples were given). For a project that has
not undergone scientific review or whose investigator is
unsure of the need for REC review, the scrutiny of a
‘scientific officer’ within COREC should be required; the
skills and qualifications required of these officers were not
specified.
Thirdly, the report perceives over-capacity in the
REC system. It recommends rationalizing the number of
RECs and their membership so that fewer RECs meet more
frequently and run a lower risk of becoming inquorate. The
report emphasizes how REC membership should be
independent of researchers, hosts and sponsors. The
Advisory Group found voluntary membership of RECs to
be unsustainable because, with a new streamlined design
(Annex 3 of their report), REC members’ time
commitment should be formally recognized, members
should be paid, and voluntary membership is likely to
under-represent certain segments of society.
Lastly, researchers’ fundamental remaining concern is
with the last hurdle they have to cross once they have
obtained funding and REC approval for their project:
obtaining permission to conduct the research from host
institutions’ R&D departments. The DoH report agrees that
the process of both site-specific assessment (for multicentre
studies) as well as approval by each host organization’s R&D
department is ‘. . . cumbersome, and it would appear to add
little value . . .’. 445
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THE REMAINING CHALLENGES
International research would be facilitated by consistent
international standards of ethical review and REC operating
procedures.43,44 The DoH report recognizes that the UK is
in advance of the rest of the European Community in
meeting the requirements of the European Clinical Trials
Directive. If the report’s recommendations for a ‘step
change’ in REC operation and the quality of ethical review
are heeded by the National Patient Safety Agency (soon to
consult on how to implement the recommendations), the
UK REC system could be a prototype for RECs across the
world.
There is an urgent need to heed the ‘most pressing’ of
all the DoH report’s recommendations, which is to
amalgamate researchers’ applications for site-specific
assessments of multicentre studies with applications
for R&D approval. The DoH report states that
‘ . . . responsibility for site-specific assessment should be
transferred to NHS hosts . . . ’ and imaginative ways of
harmonizing ethical review and research governance across
the UK are needed. These should expand on innovations
such as the new online R&D application form
(www.rdform.org.uk), which is now segregated from
COREC applications but is populated by data from the
online COREC form (and vice versa). Anecdotal reports
indicate that approximately half of R&D departments
accept this new form—the other half require researchers
to use a form particular to the R&D department in
question. These R&D departments are thwarting laudable
efforts to standardize, streamline, and speed up the process
of gaining regulatory approval, provoking comparisons
with the LRECs of yesteryear. Even when REC and R&D
approval has been obtained, another local governance
requirement that further slows down multicentre studies
(especially clinical trials) is the need for a chief investigator
or member of their team to have an honorary contract at
every local site.
The DoH has accepted the report’s recommendations
for England, but they must be applied consistently in
England, Wales, Northern Ireland, and Scotland. Harmo-
nization across the UK is vital.
The DoH report found researchers’ understanding of
ethical issues to be ‘very variable’, and there is no doubt
that researchers must ensure they are up to date with
current legislation, professional guidance, and REC process
(www.corec.org.uk). Furthermore, researchers must
continue to evaluate regulatory systems: proof is
required that COREC has achieved its timelines, and
R&D departments must be held to account for any
excessive delays they contribute to ethical research. Many
pressures have driven change in the regulation of clinical
research, not least researchers’ independent evaluations of
the system.
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